New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2012
20:54 EDTDKS, CLNE, PFE, WYNN, ACI, SWI, WFC, CAB, AAPL, JNJ, KITD, BAC, LEG, JPM, CLH, GOOG, MMM, ACAS, VOD, LVS, ECYTJim Cramer's "Mad Money"
Jim Cramer said that all of last month's winners got pummeled Monday, while a whole new class of stocks became 'en vogue'. He said for weeks, hedge fund managers have been betting hundreds of billions on continued weakness in Europe. So today, when the U.S. dollar reversed course and took a turn for the better, many managers were caught on the wrong side of the trade. That explains the action in many weak dollar stocks like 3M (MMM), Johnson & Johnson (JNJ) and Pfizer (PFE), said Cramer. These stocks, along with many of the banks, all saw their shares slide Monday. Then there are the Nasdaq darlings, Google (GOOG) and Apple (AAPL). Cramer said that while Google's slide was due to weak earnings and a questionable stock split, Apple's slide seems to be one in sympathy with the search engine giant. Cramer said there are many fund managers who would love to see shares of Apple lower, which explains many of the rumors swirling about telcos becoming unwilling to pay sky-high iPhone subsidies. He said the selling in Apple could also simply be investors taking profits to pay their taxes. But whatever the reasons for all of the selling in the markets, Cramer said the fact remains that high-quality growth stocks of all kinds are now on sale and remain a great place in which to invest. EXECUTIVE DECISION: Cramer checked back in with Andrew Littlefair, president and CEO of Clean Energy Fuels (CLNE), a stock that's up 61% since Cramer last spoke with Littlefair on Nov. 14. Cramer said that Clean Energy Fuels remains a speculative stock, adding that investors should do their homework before buying in. Cramer also spoke with Alan McKim, chairman, president and CEO of Clean Harbors (CLH), an environmental clean up company focused in the oil and natural gas industries. McKim once again touted Clean Harbors' incinerator business as a bright spot for the company. Cramer continued his recommendation of Clean Harbors. Cramer said that investors need to be able to pick the best stocks in a stock picker’s market. He compared Cabella's (CAB) to Dick's Sporting Goods (DKS) to find out which one reigns supreme in the hunting, fishing and sporting goods arena. According to Cramer, Cabella's has Dick's beat on store growth plans, same-store sales growth and higher private label sales. Also, the fact that its stock is cheap, trading at just 13x earnings compared to 17x for Dick's, makes things that much sweeter. NO HUDDLE OFFENSE: Cramer opined on earnings from JPMorgan Chase (JPM) and Wells Fargo (WFC). He said, earnings at these banks were superb. LIGHTNING ROUND: (Bullish) ECYT, LEG, SWI, LVS. (Bearish) BAC, ACI, VOD, KITD, WYNN, ACAS. Reference Link
News For MMM;JNJ;PFE;GOOG;AAPL;CLNE;CLH;CAB;DKS;JPM;WFC;ECYT;LEG;SWI;LVS;BAC;ACI;VOD;KITD;WYNN;ACAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
December 9, 2014
06:14 EDTGOOGGoogle launches Street View in Dubai
Subscribe for More Information
06:00 EDTGOOGSalesforce.com names YouTube CEO Susan Wojcicki to board
Subscribe for More Information
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
16:00 EDTBAC, AAPLOptions Update; December 8, 2014
Subscribe for More Information
15:26 EDTWFCDeutsche Bank sued by U.S. over alleged scheme to avoid income taxes
Subscribe for More Information
13:32 EDTPFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
13:16 EDTAAPLApple trades off session lows, levels to watch
Subscribe for More Information
10:00 EDTWFC, CLNEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
07:52 EDTWFCWells Fargo downgraded to Market Perform from Outperform at Bernstein
Subscribe for More Information
06:37 EDTAAPLApple rumored to be launching 4-inch iPhone in 2015, Times of India reports
Apple is rumored to be developing a new iPhone with a 4-inch display, The Times of India reports, citing a report from The Electronic Times of Taiwan. According to supply chain sources, the device will launch in 2H15. Reference Link
06:35 EDTJPM, BAC, WFCValue of Wall Street's M&A bankers has risen, NY Times says
The value of Wall Street's bankers who advise large companies seems to be increasing, while traders are becoming less valuable, according to The New York Times. Bankers who work on M&A deals are expecting their bonuses to increase, while traders anticipate that their compensation will drop, the newspaper added. Furthermore, banks seem to be going the extra mile to hire top notch bankers, the newspaper stated. Publicly traded large banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
06:22 EDTAAPLApple price target raised to $135 from $120 at Citigroup
Citigroup raised its earnings estimates for Apple after its field work indicated consumers are increasingly buying the higher memory iPhone 6 and 6+. Citi expects purchasing trends towards higher memory devices to drive stronger sales and margins. It believes consensus estimates are yet to factor in this development. The firm raised its price target for Apple shares to $135 from $120 and keeps a Buy rating on the name. Shares of phone maker closed Friday down 49c to $115.
06:21 EDTJPMDeadline for Petsmart bidders extended as lenders put on leash, NY Post reports
Subscribe for More Information
06:15 EDTAAPLLenovo shipments expected to lead Samsung by 9M in 2015, DigiTimes reports
Lenovo (LNVGY) is estimated to beat Samsung (SSNLF) in mobile device shipments in 2015 by about 9M units, reports DigiTimes Research. Lenovo is set to beat Samsung by about 1M units in 2014 and become the second largest mobile computing device brand vendor worldwide behind Apple (AAPL). DigiTimes Research says Lenovo and Samsung plan to focus on maintaining tablet shipments as demand weakens in 2015. Reference Link
05:42 EDTCLNEClean Energy downgraded to Hold from Buy at Ascendiant
Subscribe for More Information
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
13:47 EDTGOOGGoogle could reach $634 in a year, Barron's says
Google shares look attractive at current levels and shares could reach $634.00 in a year, driven by stabilizing ad pricing, Barron's contends in a feature article. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use